Immunomedics Company Profile

08:07 EDT 21st September 2017 | BioPortfolio

Immunomedics is a New Jersey-based biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. We have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or “naked” form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create highly targeted agents. Using these technologies, we have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. We have recently licensed our lead product candidate, epratuzumab, to UCB, S.A. for the treatment of all autoimmune disease indications worldwide. We have retained the rights for epratuzumab in oncology indications for which UCB has been granted a buy-in option. UCB has development, manufacture and commercialization rights, and is responsible for all clinical trials evaluating epratuzumab for the treatment of patients with moderate and severe lupus. At present, there is no cure for lupus and no new lupus drug has been approved in the U.S. in the last 40 years. We believe that our portfolio of intellectual property, which includes approximately 108 patents issued in the United States, and more than 250 other issued patents worldwide, protects our product candidates and technologies. We also have a majority ownership in IBC Pharmaceuticals, Inc., which is developing a novel dock and lock methodology, and a new method of delivering imaging and therapeutic agents selectively to disease, especially different solid cancers (colorectal, lung, pancreas, etc.), by proprietary, antibody-based, pretargeting methods. We have transitioned our focus away from the development of diagnostic imaging products in order to accelerate the development of our therapeutic product candidates. Consistent with our de-emphasis on our diagnostic business, we no longer commercialize CEA-Scan®. LeukoScan® will continue to be manufactured and commercialized by us in territories where regulatory approvals have been granted. Furthermore, as of June 30, 2006, research and development into diagnostic product candidates was no longer a material portion of our business.


300 American Road
Morris Plains
United States of America


Phone: 973 605 8200
Fax: 973 605 8282

News Articles [47 Associated News Articles listed on BioPortfolio]

VenBio Settles Immunomedics Litigation, SeaGen Nixes Cancer Drug Deal

A venBio campaign against a drug licensing deal between Immunomedics and Seattle Genetics has unwound the pact altogether. Three months after dealing for rights to an experimental breast cancer therap...

Immunomedics CEO, CSO Resign in Settlement Ending Seattle Genetics Alliance

Immunomedics President and CEO Cynthia L. Sullivan, and CSO and chief patent officer David M. Goldenberg, have resigned from their leadership positions as part of a settlement of a legal dispute with ...

Seattle Genetics Terminates License Agreement with Immunomedics

BOTHELL, Wash.–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today announced that it has agreed to terminate its license agreement with Immunomedic...

Immunomedics raises $125mm through preferred stock sale amid termination of IMU132 deal

Immunomedics Inc. (cancer and autoimmune disease therapies) grossed $125mm through the private placement to institutional investors of Series A-1 convertible shares at $125 apiece; the shares convert ...

Immunomedics Stock Has Its Sights Set on Higher Prices

IMMU Stock: Bullish on Multiple Time Frames The focus of this publication is Immunomedics, Inc. (NASDAQ: IMMU) stock. This clinical stage biotechnology company develops treatments to boost the body.....

A $2B oncology deal goes bust at the hands of an activist investor

Activist investor venBio had a good Friday. Seattle Genetics and Immunomedics did not. The two latter companies agreed to fold on their $2 billion

Seattle Genetics Terminates License Deal With Immunomedics For IMMU-132

WASHINGTON (dpa-AFX) - Seattle Genetics Inc. (SGEN) said it has agreed to terminate its license agreement with Immunomedics, Inc. (IMMU) for sacituzumab govitecan or IMMU-132 and settle the relate...

Deal Watch: Seattle Genetics' Controversial Collaboration With Immunomedics Topples

A licensing deal between the two cancer-focused biotechs falls apart amidst investor unrest at Immunomedics. Novartis opts to license Conatus'...  

Drugs and Medications [0 Results]


PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

Patent trend and competitive analysis of cancer immunotherapy in the United States.

Immunotherapy has brought high hopes for cancer treatment, and attracted tremendous resources from the biopharmaceutical community. Here we analyze cancer immunotherapy-related patents granted by the ...

Clinical Trials [0 Results]


Companies [2 Associated Companies listed on BioPortfolio]

Immunomedics, Inc.

Immunomedics (the “Company”) is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune...


Immunomedics is a New Jersey-based biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseas...

More Information about "Immunomedics" on BioPortfolio

We have published hundreds of Immunomedics news stories on BioPortfolio along with dozens of Immunomedics Clinical Trials and PubMed Articles about Immunomedics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Immunomedics Companies in our database. You can also find out about relevant Immunomedics Drugs and Medications on this site too.

Quick Search

Relevant Topics

Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...

Autoimmune Disorders
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...

Corporate Database Quicklinks

Searches Linking to this Company Record